Cleo Lee
Academic Appointments
- Postdoctoral Research fellow, Stanford Cancer Institute
Key Documents
Contact Information
- Academic Offices
Personal Information Email
Professional Overview
Honors and Awards
- AACR-Qiagen Scholar-in-Training Award, AACR (2009)
- Pre-doctoral award for prostate cancer research, US Army Department of Defense (2008-2009)
- Silver Poster Award, CIHR - Institute of Cancer Research (2007)
- The Canadian Student Health Research Forum Travel Award, CSHRF (2007)
Professional Education
| Doctor of Philosophy: | University of British Columbia (2009) |
| Bachelor of Science: | University of British Columbia, Biochemistry & Molecular Biology (2003) |
Stanford Advisors
| Maximilian Diehn: | Postdoctoral Faculty Sponsor |
Scientific Focus
Current Research Interests
It is well recognized that many human tumors contain a phenotypically unique subset of cancer cells that appears to be the sole population able to proliferate indefinitely and to form new tumors. These findings have led to the formulation of the cancer stem cell hypothesis, which proposes that cancers consist of self-renewing cancer stem cells (CSCs) and their descendent non-tumorigenic cells (NTCs) that have limited proliferative potential. Published xenograft studies have documented the existence of CSCs in leukemias and many solid tumors.
My research goals are 1). to identify genes involved in the proliferation and self-renewal of breast CSCs, and 2) to evaluate the effects of targeting self-renewal-associated genes and pathways in CSCs. It is expected that genes involved in the core self-renewal-associated signature are likely to be involved in CSC self-renewal and proliferation. The major impact of understanding breast CSC biology is that identification of genes involved in stem cell function such as self-renewal may lead to the development of improved therapies specifically targeting the breast CSCs subpopulation.
Publications
- Targeted oncolytic herpes simplex viruses for aggressive cancers. Curr Pharm Biotechnol. 2012; (9): 1786-94
- Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer. 2010; (4): 830-8
- Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol Ther. 2010; (5): 929-35
- MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res. 2009; (16): 5126-35
- An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther. 2007; (7): 652-60
- The SRS superfamily of Toxoplasma surface proteins. Int J Parasitol. 2004; (3): 285-96
Help